Bloomage Biotechnology Corporation Limited
Chinese company making hyaluronic acid ingredients and skincare brands like Runbaiyan and Quadha.
On the record
Checkpoint: Q2 2026 earnings report, watch whether skincare revenue decline decelerates or stays above 20%
The call
A profitable ingredient business is propping up a skincare brand that's losing ground to Giant Biogene quarter after quarter.
Bloomage makes hyaluronic acid (a moisturizer ingredient) that about 44% of the world buys from them, and also sells skincare products under its own brands. The ingredient business is hard to copy because it requires special fermentation know-how and regulatory approvals across 200 products, but the skincare brands are not hard to beat: a competitor called Giant Biogene grew 57% last year while Bloomage's skincare fell 32%, and the company's total revenue dropped 23% in early 2026. The one thing that matters is whether Bloomage can stop the skincare decline in the next earnings report (expected late August 2026), because if the drop keeps falling at the same steep rate, the company's turnaround plan is probably not working.
Why
01
AI pressure: None apparent. No AI product or lab is disrupting HA fermentation or skincare marketing here yet; the pressure is a human rival, not a model. Could AI do the core job? Only partly.
02
Bigger players: Giant Biogene (2367.HK). Giant Biogene's recombinant collagen line grew 57% in 2024 and 22.5% in H1 2025 while Bloomage's skincare sales fell 32%. Could a giant copy it? Probably.
03
What protects it. A B2B hyaluronic acid ingredient business with ~44% global share, 200+ regulatory approvals, and fermentation know-how rivals haven't matched.
What would change this call
Bloomage Q2 2026 earnings due Aug 28, 2026 showing skincare revenue still down 20%+. Would show the turnaround has not yet stopped the customer loss to rivals.
Giant Biogene's next quarterly report showing continued double-digit sales growth. Would confirm the rival is still converting Bloomage's former skincare customers.
Court or regulatory ruling on the 2025 Bloomage vs Giant Biogene false-advertising dispute. Could reveal further reputational damage affecting Bloomage's consumer brand trust.
Giant Biogene's next quarterly report showing continued double-digit sales growth. Would confirm the rival is still converting Bloomage's former skincare customers.
Court or regulatory ruling on the 2025 Bloomage vs Giant Biogene false-advertising dispute. Could reveal further reputational damage affecting Bloomage's consumer brand trust.
Key numbers
- Market cap down ~85% from 2021 peak of RMB 140bn
- FY2025 revenue fell 21.8% to RMB 4.20 billion
- Skincare revenue fell 32% in 2024 to RMB 2.57bn
Named risks
- Consumer skincare revenue in structural decline for four straight years with no confirmed bottom.
- Total company revenue fell 23% YoY in Q1 2026, an acceleration not a stabilization.
- Continued headcount reduction from 4,486 in 2023 to 3,972 in December 2025 signals ongoing restructuring stress.
- Reputational overhang from unresolved 2025 false-advertising dispute with Giant Biogene.
- AI integration claims in 2026 investor materials remain aspirational with no disclosed shipped product or revenue effect.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Giant Biogene | losing to | Giant Biogene revenue grew 57.2% in 2024 and 22.5% in H1 2025 while Bloomage skincare fell 32% in 2024 |
| Giant Biogene | contesting | Public false-advertising dispute in May-June 2025 sent Giant Biogene shares down ~30%, Bloomage up ~7% |
| L'Oreal | losing to | L'Oreal shipped AI-powered Modiface diagnostics and Perso personalization device in October 2024 |
| Haohai Biotech | gaining on | Haohai FY2025 revenue also fell ~8.3-8.7% YoY and net profit dropped 40.3%, a shared sector decline |
| Fufeng Group and other HA raw-material peers | contesting | Global HA raw-material manufacturers compete with Bloomage's ~44% share B2B ingredient business as of mid-2025 |
Questions people ask
- Is Bloomage Biotechnology profitable in 2026?
- Bloomage remains profitable but shrinking fast. FY2025 revenue fell 21.8% to RMB 4.20 billion, and Q1 2026 revenue dropped 23.06% YoY to RMB 829.41 million, though Q1 2026 operating cash flow turned positive at RMB 130.96 million after cost cuts, per July 2026 investor materials.
- Who is Bloomage Biotechnology's biggest competitor?
- Giant Biogene (2367.HK) is Bloomage's fiercest rival in Chinese skincare. Giant Biogene's revenue grew 57.2% in 2024 to RMB 5.5 billion and 22.5% in H1 2025 to RMB 3.113 billion, while Bloomage's functional skincare revenue fell 32% in 2024.
- Could AI replace Bloomage Biotechnology's business?
- Bloomage's core hyaluronic acid fermentation IP and 200+ regulatory SKU filings across China, EU, US and other jurisdictions are not easily AI-replicable, but its consumer skincare marketing on Douyin and Tmall faces AI personalization tools like L'Oreal's Perso device, launched October 2024.
- Why did Bloomage Biotechnology's stock crash?
- Bloomage's market cap fell roughly 85%, from about RMB 140 billion at its 2021 peak to RMB 17.5 to 26 billion by mid 2026. It was removed from the CSI 300 Index in December 2024 amid a multi-year consumer skincare revenue collapse.
- Does Bloomage Biotechnology own a large share of the hyaluronic acid market?
- Bloomage says it holds roughly 44% of the global hyaluronic acid raw-material market as of mid 2025, backed by 200-plus regulatory SKU filings across pharmaceutical, cosmetic and food grades and registrations in China, the EU, US, Japan, Korea, Russia, India and Canada.
- What happened between Bloomage and Giant Biogene in 2025?
- In May to June 2025 Bloomage publicly accused Giant Biogene of false advertising over recombinant-collagen efficacy claims. Giant Biogene shares fell about 30% during the dispute while Bloomage shares rose about 7%, per June 2025 reporting.
Timeline
- 2026-07-02Q1 2026 earnings materials cite strategic restructuring toward synthetic biology and AI integration
- 2026-03-31Q1 2026 revenue RMB 829.41 million, down 23.06% YoY; operating cash flow turns positive
- 2025-12-31FY2025 revenue falls to RMB 4.20 billion, down 21.8% YoY
- 2025-09-04Chair Zhao Yan returns to front-line operations to rebuild consumer marketing team
- 2025-06-11Bloomage accuses Giant Biogene of false advertising; Giant Biogene shares fall ~30%
- 2025-03-25Bloomage wins Cosmetics and Toiletries Alle Award for Bloomcolla Col III collagen
- 2024-12-31FY2024 revenue RMB 5.37 billion, down 11.6% YoY; net profit down 72.3% YoY
- 2024-12-31Bloomage removed from CSI 300 Index
- 2019-01Bloomage lists on Shanghai STAR Market as 688363.SH
- 2000-01-03Bloomage Biotechnology founded, headquartered in Jinan, Shandong
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Bloomage BioTechnology Corp. Ltd. A Company Profile & Executives - WSJ (2025-06-12)
- Biogene gets bruised in 'Battle of the skincare belles' (2025-06-12)
- Bloomage BioTechnology (688363) Q4 2024 Summary (2025-12-23)
- Bloomage BioTechnology Corporation (SHA) (2026-06-28)
- After years of "sleep," Bloomage faces biotech's hard realities (2025-09-17)
- Bloomage BioTechnology (688363) Investor Relations, Earnings Summary & Outlook (2026-07-02)
- Bloomage Biotechnology Number of Employees 2026 (2026-06-29)
- A Deep Dive into Reconstructing Bloomage Biotechnology (2025-09-04)
- Chinese Skincare Company Refutes 'False Advertising' Claims (2025-06-06)
- GIANT BIOGENE Revenue and Profit Both Grow in H1 2025 (2026-05-16)
- Company Profile-Bloomage Biotech
- Artificial Intelligence in the Evolution of Customized Skincare Regimens (2025-04-18)